Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

3(60.0%)

Phase 1

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 3(3)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02198794Phase 3Completed

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

Role: lead

NCT01897896Phase 3Completed

Alternatives for Reducing Chorea in Huntington Disease

Role: lead

NCT02291861Phase 3Completed

Addressing Involuntary Movements in Tardive Dyskinesia

Role: lead

NCT02674321Phase 1Completed

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)

Role: lead

NCT02195700Phase 2Completed

Aim to Reduce Movements in Tardive Dyskinesia

Role: lead

All 5 trials loaded